First in human, dose escalation study of VRN110755 in non-small cell lung cancer patients with EGFR mutations
Latest Information Update: 09 Jun 2025
At a glance
- Drugs VRN 11 (Primary) ; Afatinib; Dacomitinib; Osimertinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
Most Recent Events
- 09 Jun 2025 New trial record
- 30 Apr 2025 Results assessing safety, pharmacokinetics, and early efficacy of VRN-11 in patients with non-small cell lung cancer patients were presented at the 116th Annual Meeting of the American Association for Cancer Research